Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma: BENCART Trial

Next Previous
Trial Profile

A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma: BENCART Trial

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2018

At a glance

  • Drugs Bendamustine (Primary) ; Carboplatin (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary)
  • Indications Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms BENCART

    • Most Recent Events

    • 04 Sep 2018 Status changed from active, no longer recruiting to completed.
    • 31 Aug 2018 Biomarkers information updated
    • 19 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top